Peptide Absorption: How Different Routes Affect Bioavailability

Bioavailability (F) is the fraction of an administered compound that reaches systemic circulation in its active form. Intravenous administration provides 100% bioavailability by definition, as the compound is delivered directly into the bloodstream. All other routes of administration result in some degree of loss due to incomplete absorption, first-pass metabolism, enzymatic degradation, or physical barriers.

For peptide research, bioavailability directly impacts experimental outcomes. A peptide administered by a route with low bioavailability may appear less potent than it actually is, leading to incorrect conclusions about dose-response relationships. Understanding the bioavailability characteristics of different administration routes allows researchers to interpret their data accurately and select the most appropriate route for their experimental objectives.

Peptides face several biological barriers that limit absorption across epithelial surfaces. Enzymatic degradation by proteases (pepsin, trypsin, chymotrypsin in the GI tract; aminopeptidases on cell surfaces) rapidly cleaves peptide bonds, reducing the intact peptide available for absorption. The size and hydrophilicity of most peptides prevent passive diffusion across lipid bilayer membranes. The tight junctions between epithelial cells limit paracellular transport for all but the smallest peptides.

Additionally, hepatic first-pass metabolism degrades peptides that are absorbed via the portal circulation (relevant for oral administration). The mucus layer coating mucosal surfaces acts as a physical barrier that reduces peptide contact with absorptive epithelium. Each of these barriers contributes to the generally low bioavailability of unmodified peptides administered by non-injection routes.

Subcutaneous (SC) injection deposits the peptide into the adipose tissue layer beneath the skin. Absorption occurs primarily through diffusion into surrounding capillaries and lymphatic vessels. The rate and extent of absorption depend on peptide molecular weight, local blood flow, injection volume, and formulation characteristics.

For most research peptides under 10 kDa, subcutaneous bioavailability ranges from 65-95%. Smaller peptides (MW < 5 kDa) are absorbed primarily through blood capillaries with rapid onset (Tmax 15-60 minutes). Larger peptides and proteins are increasingly absorbed through the lymphatic system, which provides slower absorption (Tmax 2-8 hours) but avoids first-pass hepatic metabolism. Semaglutide, for example, achieves approximately 89% subcutaneous bioavailability with a Tmax of 1-3 days due to its albumin-binding fatty acid modification.

Intravenous (IV) injection provides instantaneous, complete delivery of the peptide to systemic circulation. By definition, IV bioavailability is 100%. This route is essential for pharmacokinetic studies that need to establish the absolute bioavailability of other routes (calculated as F = AUC_route / AUC_IV) and for applications requiring immediate, precisely timed peak concentrations.

The disadvantages of IV administration in research settings include the requirement for vascular access, the risk of bolus-related adverse effects from rapid peak concentrations, and the unsuitability for self-administration in ambulatory studies. For research protocols where precise dose delivery is paramount, IV injection remains the gold standard. The 2025 pilot study of BPC-157 used IV administration specifically to establish baseline safety pharmacokinetics.

Oral administration is the most convenient route but presents the greatest challenges for peptides. The gastrointestinal tract is designed to digest proteins and peptides efficiently — the same enzymatic machinery that breaks down dietary protein destroys therapeutic peptides. For unmodified peptides, oral bioavailability is typically below 1-2%, making oral delivery impractical without formulation intervention.

Significant progress has been made in oral peptide delivery. Rybelsus (oral semaglutide) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to achieve approximately 1% oral bioavailability — low in absolute terms but sufficient for therapeutic efficacy at the 14 mg oral dose. The FDA approval of orforglipron in April 2026 represents a different approach: a non-peptide small molecule that mimics GLP-1 receptor pharmacology without the absorption limitations of peptide structures.

BPC-157 is notable for its unusual gastric acid stability, which has prompted research into oral administration routes. However, quantitative oral bioavailability data for BPC-157 in published literature remains limited, and the acid-stability advantage does not address intestinal protease degradation or membrane permeability barriers.

Intranasal delivery deposits the peptide on the nasal mucosa, which has a large surface area (approximately 150 cm2), rich vascularity, and relatively thin epithelium compared to the GI tract. Peptides absorbed through the nasal mucosa enter systemic circulation directly, bypassing hepatic first-pass metabolism. Bioavailability via the nasal route typically ranges from 10-30% for peptides under 5 kDa.

The nasal route also offers the possibility of direct nose-to-brain transport via the olfactory and trigeminal nerve pathways. This mechanism is particularly relevant for neuroactive peptides, as it bypasses the blood-brain barrier. However, the contribution of direct nose-to-brain transport relative to systemic absorption remains quantitatively uncertain for most peptides.

Transdermal delivery of peptides through intact skin is extremely limited due to the stratum corneum barrier. The stratum corneum is a lipophilic barrier approximately 10-20 micrometers thick that effectively blocks molecules larger than approximately 500 Da. Since most peptides exceed this size threshold, passive transdermal delivery achieves negligible bioavailability for systemic applications.

Physical enhancement techniques — including microneedle arrays, iontophoresis (electrical driving force), and sonophoresis (ultrasound-mediated permeabilization) — can improve transdermal peptide delivery. Microneedle patches, in particular, have shown promise for peptide delivery by creating microchannels that bypass the stratum corneum while remaining painless. Topical application for local (non-systemic) effects, such as thymosin beta-4 for corneal wound healing, avoids the need for transdermal penetration.

• Fatty acid conjugation: Attaching a lipophilic fatty acid chain (C16-C20) enables albumin binding, extending half-life and improving absorption. Used in semaglutide and tirzepatide.
• PEGylation: Conjugation with polyethylene glycol increases molecular size (reducing renal clearance), shields from proteases, and improves solubility. Widely used for therapeutic proteins.
• Protease inhibitors: Co-administration with protease inhibitors (aprotinin, bestatin) can reduce enzymatic degradation, particularly for oral delivery.
• Absorption enhancers: Compounds like SNAC (used in oral semaglutide) transiently increase epithelial permeability by disrupting tight junctions or altering membrane fluidity.
• D-amino acid substitution: Replacing L-amino acids with D-amino acids at protease-susceptible sites confers resistance to enzymatic degradation.
• Cyclization: Forming a cyclic peptide structure reduces conformational flexibility and often improves protease resistance and membrane permeability.
• Nanoparticle encapsulation: Encapsulating peptides in biodegradable nanoparticles (PLGA, chitosan) protects against degradation and can enhance mucosal uptake.

The choice of administration route in research should be driven by the experimental question. Pharmacokinetic studies require IV and at least one non-IV route for bioavailability calculation. Efficacy studies should use the route that delivers consistent, quantifiable doses — subcutaneous injection is preferred for most peptide research protocols due to its high and reproducible bioavailability.

When comparing results across published studies, researchers must account for route-dependent bioavailability differences. A peptide that appears effective at 1 mg/kg SC may require 10-100x higher doses orally to achieve equivalent systemic exposure. Failing to normalize for route-specific bioavailability is a common source of apparent contradictions between studies.

Why is oral bioavailability so low for peptides? The GI tract contains multiple protease enzymes that rapidly degrade peptides. Additionally, peptides are generally too large and hydrophilic to cross intestinal epithelial membranes by passive diffusion, and any peptide absorbed via the portal vein undergoes hepatic first-pass metabolism.

Can intranasal peptides reach the brain directly? Some evidence supports direct nose-to-brain transport via olfactory pathways, but the quantitative contribution of this route versus systemic absorption is debated. Intranasal insulin and oxytocin research suggests that CNS effects can occur faster than predicted by systemic pharmacokinetics alone.